Liraglutide hit the headlines in January because it had just been approved by the European Medicines Agency (EMA) for the treatment of obesity, to be marketed as “Saxenda”. The EMA had previously approved it for type 2 diabetes in July 2009. In America the approval for obesity had come a month earlier in December 2014.
Archive for February 13th, 2015
Developing a safe and effective […]